NOTICE OF IRB APPROVAL WITH MODIFICATIONS / REB ATTESTATION

DATE:	28 Mar 2018
TO:	Natalie Fisher University of Michigan
PROTOCOL:	National Institute of Neurologic Disorders and Stroke, NIH - Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial: A Multicenter, Randomized, Prospective Phase II Adaptive Clinical Trial Evaluating the Most Effective Hyperbaric Oxygen Treatment Paradigm for Severe Traumatic Brain Injury (Pro00024234)
APPROVAL DATE:	27 Mar 2018
EXPIRY DATE:	27 Mar 2019

IRB APPROVED DOCUMENTATION

Protocol Version:	• Protocol (Version 2, Dated 19th March 2018)
Consent Templates:	• (Canada) Informed Consent Form (IRB Services Approved Version 27 Mar 2018) • (US) Informed Consent Form (IRB Services Approved Version 27 Mar 2018)
Other Material:	• Electronic Informed Consent Screenshots (Not Dated) • SIREN Standard Operating Procedure for Electronic Informed Consent (Not Dated) • FDA Notification "Study May Proceed" (Not Dated) • Notice of Award (Federal Award Date: 09/15/2017)

The IRB approved the above referenced protocol with the modification listed below on 27 Mar 2018:

- **Revisions to the Informed Consent Forms**

Investigators may only conduct the research after receiving their IRB Approval, which will be sent separately.

IRB Approved Consent Documents

The consent documents referenced above will be personalized by IRB Services for each site.

372 Hollandview Trail | Suite 300 | Aurora, Ontario, Canada L4G 0A5
irbservices.com | Office: 905.727.7989 | Fax: 905.727.7990

The IRB reviewed the project in accordance with the 21 CFR Part 50, Subpart D Federal Regulations and 45 CFR Part 46, Subpart D Federal Regulations which provide for additional protections for children as research subjects.

The IRB determined that the research study meets the criteria found in the risk category described as follows:

- 21 CFR 50.52 and 45 CFR 46.405: "*Research involving greater than minimal risk but presenting the prospect of direct benefit to the individual subjects*." *Permission of one parent is required.*

Membership List / Investigator Responsibilities

You can access a copy of the most recent IRB membership list located in the "Reference Materials" section of CIRBI™ (www.cirbi.net).

Investigator responsibilities are defined in pertinent regulations and ICH GCP Guidelines, as well as the *General Guidance: Investigator Responsibilities* located in the "Reference Materials" section of CIRBI™ (www.cirbi.net).

Compliance Statement/Attestation

IRB Services attests that the documents have been approved, as described above, and the membership of the IRB complies with the requirements defined in Health Canada regulations, 21 CFR parts 56 and 312.3 and 45 CFR 46. The IRB carries out its functions in accordance with good clinical practices (e.g., ICH GCP Guidelines) and Health Canada regulations and in compliance with FDA 21 CFR parts 50 and 56, DHHS 45 CFR part 46, and the Tri-Council Policy Statement for Ethical Conduct of Research Involving Humans, as appropriate to the research.

The IRBs of IRB Services are registered with OHRP and FDA as follows:
- ON IRB registration #IRB00000776
- QC IRB registration #IRB00005290

Continuing review

The IRB is responsible for continuing review of the research. Any modifications to the research (including but not limited to changes to the protocol or informed consent document(s), new or revised recruitment materials, change of site information, change of investigator, etc.) must receive IRB approval prior to implementation of the changes, except to remove an immediate hazard or in case of minor administrative changes.

In the event that conduct of this study will exceed the approval period granted by the IRB (usually one year) please complete a *Continuing Review Report* to request an extension of IRB approval of the research prior to approval expiry. Notification of an upcoming continuing review and the information required for submission to the IRB will be communicated to you and the investigators in advance of the submission deadline. The completed *Continuing Review Reports* must be received at IRB Services and reviewed by the IRB prior to the expiration date in order to ensure that the ethics approval of the research is maintained.

At the end of the study, please complete a *Termination Report* and submit it to IRB Services.

If you have any questions, please do not hesitate to contact us at 905-727-7989 or via Contact IRB in CIRBI.

Association for the Accreditation of Human Research Protection Programs, Inc. Full Accreditation
372 Hollandview Trail | Suite 300 | Aurora, Ontario, Canada L4G 0A5
irbservices.com | Office: 905.727.7989 | Fax: 905.727.7990

Thank you for selecting IRB Services to review your research project.

Sincerely,

Sarah Weir

Sarah Weir, CIP
Client Services Coordinator, Chesapeake IRB
On behalf of Institutional Review Board Services

Association for the Accreditation of Human Research Protection Programs, Inc. Full Accreditation

372 Hollandview Trail | Suite 300 | Aurora, Ontario, Canada L4G 0A5
irbservices.com | Office: 905.727.7989 | Fax: 905.727.7990

IRB APPROVAL/REB ATTESTATION

MOD00258578

DATE:	4 Apr 2018
TO:	Natalie Fisher University of Michigan
PROTOCOL:	National Institute of Neurologic Disorders and Stroke, NIH -, Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial: A Multicenter, Randomized, Prospective Phase II Adaptive Clinical Trial Evaluating the Most Effective Hyperbaric Oxygen Treatment Paradigm for Severe Traumatic Brain Injury (Pro00024234)
APPROVAL DATE:	4 Apr 2018

IRB APPROVED DOCUMENTATION

Consent Templates:

- (Canada) Informed Consent Form (IRB Services Approved Version 4 Apr 2018)
- (US) Informed Consent Form (IRB Services Approved Version 4 Apr 2018)

The IRB reviewed and approved the above referenced documentation.

Current IRB Approved Consent Documents

The new Consent Forms referenced above are now available on your CIRBI workspace.

The consent documents referenced above will be personalized by IRB Services for each site.

Membership List

You can access a copy of the most recent IRB membership list located in the "Reference Materials" section of CIRBI™ (www.cirbi.net).

Investigator Responsibilities

Investigator responsibilities are defined in pertinent regulations and ICH GCP Guidelines, as well as the *General Guidance: Investigator Responsibilities* located in the "Reference Materials" section of CIRBI™ (www.cirbi.net).

Compliance Statement/Attestation

IRB Services attests that the above document(s) have been approved, as described above, and the membership of the IRB complies with the requirements defined in Health Canada regulations, 21 CFR parts 56 and 312.3 and 45 CFR 46. The IRB carries out its functions in accordance with good clinical

372 Hollandview Trail | Suite 300 | Aurora, Ontario, Canada L4G 0A5
irbservices.com | Office: 905.727.7989 | Fax: 905.727.7990

practices (e.g., ICH GCP Guidelines) and Health Canada regulations and in compliance with FDA 21 CFR parts 50 and 56, DHHS 45 CFR part 46, and the Tri-Council Policy Statement for Ethical Conduct of Research Involving Humans, as appropriate to the research.

The IRBs of IRB Services are registered with OHRP and FDA as follows:
- ON IRB registration #IRB00000776
- QC IRB registration #IRB00005290

If you have any questions, please do not hesitate to contact us at 905-727-7989 or via Contact IRB in CIRBI.

Thank you for selecting IRB Services to review your research project.

Sincerely,

Sarah Weir

Sarah Weir, CIP
Client Services Coordinator, Chesapeake IRB
On behalf of Institutional Review Board Services

Full Accreditation
372 Hollandview Trail | Suite 300 | Aurora, Ontario, Canada L4G 0A5
irbservices.com | Office: 905.727.7989 | Fax: 905.727.7990